Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00270725 |
Recruitment Status
:
Withdrawn
(Enrollment never initiated, study withdrawn.)
First Posted
: December 28, 2005
Last Update Posted
: February 28, 2017
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | December 27, 2005 | |||
First Posted Date | December 28, 2005 | |||
Last Update Posted Date | February 28, 2017 | |||
Actual Study Start Date | July 1, 2005 | |||
Actual Primary Completion Date | July 1, 2005 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures | Not Provided | |||
Original Primary Outcome Measures | Not Provided | |||
Change History | Complete list of historical versions of study NCT00270725 on ClinicalTrials.gov Archive Site | |||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Outcome Measures | Not Provided | |||
Original Other Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa | |||
Official Title | The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS | |||
Brief Summary | The purpose of this study is to determine the impact of anti-HIV treatment on the work attendance of employed people in South Africa. The study will enroll participants from a large manufacturing and distribution firm in South Africa. | |||
Detailed Description | Little is known about the economic benefits of providing antiretroviral therapy (ART) for HIV infected patients in sub-Saharan Africa and other resource-limited areas. In South Africa, an increasing number of private sector firms are providing access to ART for their employees. One of the barriers to such action, however, is the lack of available information on the success of ART in restoring workers to full productivity, retaining skilled employees in the workforce, and reducing the costs of medical care and death and disability benefits. HIV infected employees on ART may be absent from work less often than untreated HIV infected employees, but more often than HIV uninfected employees. This study will collect data from an independent HIV/AIDS disease treatment program and a large private sector employer in Johannesburg, South Africa to estimate the benefits and costs for businesses to provide ART to eligible employees. The study will combine individual-level medical outcome and treatment cost data from the treatment program with data on employee work attendance and retention in the workforce from the participating employer. The work attendance of HIV infected employees enrolled in the HIV/AIDS treatment program (index participants) who are either taking ART or receiving pre-ART care will be compared with each other and with that of HIV uninfected employees. There are no study visits associated with this study; all data will be collected from medical records maintained by the HIV/AIDS treatment program and the participants' employer. The financial costs and benefits of the treatment program for the participating company will also be estimated. |
|||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Retrospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | see elig | |||
Condition | HIV Infections | |||
Intervention | Not Provided | |||
Study Groups/Cohorts | Not Provided | |||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Withdrawn | |||
Actual Enrollment |
0 | |||
Original Enrollment |
120 | |||
Actual Study Completion Date | July 1, 2005 | |||
Actual Primary Completion Date | July 1, 2005 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria for All Participants:
Inclusion Criteria for Index Participants:
Exclusion Criteria for Index Participants:
|
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Senior) | |||
Accepts Healthy Volunteers | Yes | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | South Africa | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00270725 | |||
Other Study ID Numbers | RTC-BU-01 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Sydney Rosen, Boston University | |||
Study Sponsor | Boston University | |||
Collaborators | United States Agency for International Development (USAID) | |||
Investigators |
|
|||
PRS Account | Boston University | |||
Verification Date | February 2017 |